Boston court rules in favor of AstraZeneca's 'pay-for-delay' deal involving Nexium

A federal jury in Massachusetts has ruled in favor of AstraZeneca Plc and Ranbaxy Laboratories following accusations that the companies delayed the launch of a generic version of the heartburn drug Nexium, sparing the companies potentially billions in damages. The verdict was handed down Friday in federal court in Boston. The lawsuit began in 2012 and was filed by plaintiffs including drug wholesalers, retailers and insurance companies. The plaintiffs claimed that the two companies agreed to a…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news